<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eva Krishna Sutedja</style></author><author><style face="normal" font="default" size="100%">Frizam Dwindamuldan Sutisna</style></author><author><style face="normal" font="default" size="100%">Endang Sutedja</style></author><author><style face="normal" font="default" size="100%">Kartika Ruchiatan</style></author><author><style face="normal" font="default" size="100%">Yogi Faldian</style></author><author><style face="normal" font="default" size="100%">Laila Tsaqilah</style></author><author><style face="normal" font="default" size="100%">Hermin Aminah Usman</style></author><author><style face="normal" font="default" size="100%">Yovan Rivanzah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Poikilodermatous Mycosis Fungoides: A Rare Case Treated with Low-Dose Methotrexate</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cutaneous T-cell lymphoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Methotrexate</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycosis fungoides</style></keyword><keyword><style  face="normal" font="default" size="100%">Poikilodermatous mycosis fungoides</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">276-279</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Mycosis fungoides (MF) is a subtype of cutaneous T-cell lymphoma (CTCL) and a primary cutaneous lymphoma. Poikilodermatous MF (PMF) is a rare clinical variant of MF. Systemic chemotherapy, such as methotrexate (MTX), may be administered as monotherapy or in combination at low doses in MF. A 64-year-old man with PMF has been reported. History and physical examination revealed hyperpigmented and hypopigmented macules on the chest, abdomen, both arms, back, and upper legs, along with erythematous macules on the right medial thigh. The diagnosis of PMF is based on clinical manifestations and histopathological features of atypical lymphocyte cell infiltration in the epidermis. In addition, immunohistochemical examination also supports the MF diagnosis. The patient received chemotherapy consisting of monotherapy with MTX at low doses. During the third month of observation following MTX therapy, a few of the hyperpigmented and hypopigmented macules appeared to have diminished; some of the erythematous macules had transformed into hyperpigmented macules, and there were no new lesions. The purpose of therapy is to control the disease. Administration of low-dose MTX as a monotherapy may result in clinical improvement, but further observation is necessary. PMF may have a better prognosis than other clinical variants of MF.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><section><style face="normal" font="default" size="100%">276</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Eva Krishna Sutedja&lt;sup&gt;1&lt;/sup&gt;*, Frizam Dwindamuldan Sutisna&lt;sup&gt;1&lt;/sup&gt;, Endang Sutedja&lt;sup&gt;1&lt;/sup&gt;, Kartika Ruchiatan&lt;sup&gt;1&lt;/sup&gt;, Yogi Faldian&lt;sup&gt;1&lt;/sup&gt;, Laila Tsaqilah&lt;sup&gt;1&lt;/sup&gt;, Hermin Aminah Usman&lt;sup&gt;2&lt;/sup&gt;, Yovan Rivanzah&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jimenez-Arellanes Maria Adelina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-TB drugs</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatoprotector</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatotoxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Methotrexate</style></keyword><keyword><style  face="normal" font="default" size="100%">Nephroprotector</style></keyword><keyword><style  face="normal" font="default" size="100%">Silybin</style></keyword><keyword><style  face="normal" font="default" size="100%">Silymarin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">358-368</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The liver is the organ in charge of homeostasis and metabolism of sundry substances (endogenous and exogenous, including drugs); but when these are metabolized, they generate more toxic and/or reactive metabolites, that can damage the liver causing cirrhosis, steatosis and/or hepatocarcinoma. Human have been used several medicinal plants (MP) since ancestral times to treat their ailments, diseases and liver disorders, including&lt;em&gt; Sylibum marianum&lt;/em&gt;. This MP is used in the treatment of jaundice and other biliary diseases, as well as in support therapy for edible mushrooms poisoning and in the treatment of some hepatic diseases. From this medicinal plant, silymarin (SLM, mixture of flavonoids) is obtained, it has an important antioxidant, anti-inflammatory and hepatoprotector effect. The last activity has been demonstrated through several preclinical and in some clinical studies. To date, a few clinical studies describe the hepatoprotective and/or nephroprotective effect of SLM against the damage caused by anti- TB drugs, methotrexate and in cases of type II diabetes mellitus or chronic hepatitis C. Nevertheless, this type of research is more frequent in preclinical trials (using rats or mice) or in vitro assay.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><section><style face="normal" font="default" size="100%">358</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Jimenez-Arellanes Maria Adelina&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Unidad de Investigación Médica en Farmacología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Av. Cuauhtémoc 330, Col. Doctores, Delg, Cuauhtémoc 06720, CDMX, MEXICO.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Godishala Shirisha</style></author><author><style face="normal" font="default" size="100%">Kiranmai Mandava</style></author><author><style face="normal" font="default" size="100%">Uma Rajeswari Batchu</style></author><author><style face="normal" font="default" size="100%">Kesava Rao Thammana</style></author><author><style face="normal" font="default" size="100%">Vijaya Laxmi Turpu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antitumor and Antioxidant Effects of Flavonoid Fraction of Citrus sinensis peel Extract</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Dalton lymphoma ascites</style></keyword><keyword><style  face="normal" font="default" size="100%">Ethidium bromide</style></keyword><keyword><style  face="normal" font="default" size="100%">Methotrexate</style></keyword><keyword><style  face="normal" font="default" size="100%">Orange peel flavonoids</style></keyword><keyword><style  face="normal" font="default" size="100%">Tryphan blue</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2019</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">57-63</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Background:&lt;/strong&gt; Cancer is one of the leading causes of death and globally the numbers of cases of cancer are increasing gradually. However, surgeries, chemotherapies have become safer, but these treatments have debilitating side effects. Flavonoids present in the human diet comprise many polyphenolic secondary metabolites with broad-spectrum pharmacological activities including their potential role as anti-cancer agents. &lt;strong&gt;Objective:&lt;/strong&gt; The objective of the present study was to extract, orange peel flavonoids (Orange Peel Extract) and to screen anticancer potential of OPF. &lt;strong&gt;Methods:&lt;/strong&gt; In the present study tryphan blue dye exclusion, clonogenic assay and nuclear damage studies by ethidium bromide staining were performed to estimate &lt;em&gt;in vitro&lt;/em&gt; antitumor properties of Orange Peel Extract and subsequently &lt;em&gt;in vivo&lt;/em&gt; studies also performed using the Dalton lymphoma ascites (DLA) tumor model in Swiss albino mice. &lt;strong&gt;Results:&lt;/strong&gt;&lt;em&gt; In vitro&lt;/em&gt; studies revealed the moderate toxicity, high regenerative capacity of Orange Peel Extract and also showed changes in nuclear morphology similar to that of apoptotic cells which is one of the important aspect of an anticancer drug. &lt;em&gt;In vivo&lt;/em&gt; studies confirmed the anticancer activity of Orange Peel Extract and has increased the average life span of treated animals and restored the antioxidant enzyme levels and hematological parameters to normal which was comparable to that of standard methotrexate. &lt;strong&gt;Conclusion:&lt;/strong&gt; Overall, these findings have proved that out of the two doses (50mg/kg bw and 200mg/kg bw) employed for the study lower dose (50mg/kg) was found to be more effective than higher dose (200mg/ kg). Hence flavonoid fraction of orange peels can be the better alternative to treat cancer.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">57</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Godishala Shirisha&lt;sup&gt;1&lt;/sup&gt;, Kiranmai Mandava&lt;sup&gt;*2&lt;/sup&gt;, Uma Rajeswari Batchu&lt;sup&gt;2&lt;/sup&gt;, Kesava Rao Thammana&lt;sup&gt;2&lt;/sup&gt;, Vijaya Laxmi Turpu&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, Ootacamund Tamil nadu 643001, INDIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pharmaceutical Chemistry, Bharat Institute of Technology, Ranga Reddy District, Telangana 501510, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>